Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis
Frontiers in Oncology · 22.07.2026 · 16
DOI: 10.3389/fonc.2026.1766549 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 22.07.2026. Verfasst von Shuai Tan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capi…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Aplastic anemia (AA) is a bone marrow failure syndrome. Whether the combination of TPO-RAs and IST is superior to IST alone is an ongoing debate. This meta-analysis compares the efficacy of EPAG+IST versus IST alone, and assesses the initiation timing and treatment duration of eltrombopag (EPAG) across different age groups of AA patients.
Methods
The literature was retrieved from Chinese and English databases up to October 1, 2025. The analysis was conducted using RevMan 5.4 software, employing a fixed-effects model to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the outcomes. The I² statistic was used to assess heterogeneity among included studies.
Results
21 studies involving 2,239 patients were included. The overall response rate in the EPAG+IST group was higher at 3 months (OR = 2.13, 95% CI 1.65 – 2.74, P < 0.00001) and 6 months (OR = 2.13, 95% CI 1.73 – 2.61, P < 0.00001). There was no significant difference between the two groups at 12 months (OR = 1.14, 95% CI 0.86 – 1.51, P = 0.36, I² = 35%).
Conclusion
The addition of EPAG to IST may improve early hematological responses at 3 and 6 months in patients with AA, with no significant difference at 12 months. Concurrent initiation (within 7 days) was associated with earlier responses in adults. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024604778
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU), Beijing, China.
- Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU), Beijing, China.
Zitieren
APA
Tan, S., Shang, M., Guo, Y., Su, L., Wang, H., Ma, Q., Hui, W., Ni, J., Cai, Z., He, H., Cao, Y., Li, Y., Li, Y., Chen, Y., Sun, J., & Sun, W. (2026). Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1766549
Vancouver
Tan S, Shang M, Guo Y, Su L, Wang H, Ma Q, et al. Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1766549
BibTeX
@article{Tan2026,
author = {Tan, Shuai and Shang, Mingyue and Guo, Yixian and Su, Li and Wang, Huanyuan and Ma, Qiang and Hui, Wuhan and Ni, Jing and Cai, Zehao and He, Huizhen and Cao, Yaofang and Li, Yuxin and Li, Yumeng and Chen, Yaochi and Sun, Jing and Sun, Wanling},
title = {Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1766549}
}
EUVIMED